https://www.optimumcomms.com/wp-content/uploads/2024/02/Bionical_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-29 08:34:562024-02-29 15:12:56Bionical Solutions Appoints Chief Technology Officer to Create Innovative Data Products and Software for the Digital Business
https://www.optimumcomms.com/wp-content/uploads/2023/08/Bioinnovation_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-29 08:19:122024-02-29 08:20:00BII welcomes twelve new companies to its Venture Lab program
https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-27 08:28:062024-02-27 08:28:06Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-26 12:25:442024-02-26 12:25:44Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis
https://www.optimumcomms.com/wp-content/uploads/2024/02/Kling_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-22 14:55:152024-02-23 08:55:54Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-22 08:45:112024-02-22 08:45:11STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-22 08:43:102024-02-22 08:43:10Researchers aim to advance quantum sensing to transform disease diagnosis and prevention
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-21 08:46:252024-02-22 08:48:59Calliditas Year-end report, January – December 2023
https://www.optimumcomms.com/wp-content/uploads/2023/08/Rejuvenate_-Biomed_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-21 08:12:322024-02-21 08:12:32Rejuvenate Biomed’s clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-15 08:37:272024-02-15 08:37:27Poolbeg Pharma plc – Board Role Change and Launch of Employee Performance Incentive Plan
https://www.optimumcomms.com/wp-content/uploads/2024/01/DelSiTech_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-13 08:08:102024-02-13 08:08:10DelSiTech and Tolmar Announce Global License and Development Agreement
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-12 08:38:242024-02-12 08:38:24Poolbeg Pharma plc – Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
https://www.optimumcomms.com/wp-content/uploads/2024/02/Alys_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-12 08:19:252024-02-12 08:40:35Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/06/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-09 08:08:432024-02-13 08:10:09Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
https://www.optimumcomms.com/wp-content/uploads/2023/08/Invizius_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-07 08:36:542024-02-07 08:36:54Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-07 08:35:252024-02-07 08:35:25Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-06 08:39:582024-02-07 08:40:10Novo Holdings invests in Manipal Hospitals, a leading private hospital chain in India
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neophare_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-01 08:38:352024-02-01 08:38:35NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-26 13:00:232024-01-26 13:53:42Update on Regulatory Review of leriglitazone in the EU
https://www.optimumcomms.com/wp-content/uploads/2023/06/Breye_Logo_300x180px-80x80-6.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-25 08:39:122024-01-25 08:39:12Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic RetinopathyFor more information about Optimum Strategic Communications, please get in touch.
